Lexicon Pharmaceuticals (NASDAQ: LXRX) files Q3 2025 results 8-K

Rhea-AI Filing Summary

Lexicon Pharmaceuticals, Inc. furnished a Form 8-K to disclose that it issued a press release reporting financial results for the quarter ended September 30, 2025.

The press release is provided as Exhibit 99.1 and the company states that the information in this report and the exhibit is being furnished under Item 2.02 for results of operations and financial condition, rather than filed for purposes of Exchange Act liability or incorporation by reference.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001062822FALSE00010628222025-08-062025-08-0600010628222025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 8-K

__________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Lexicon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware			000-30111			76-0474169
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification Number)

2445 Technology Forest Blvd., 11th Floor

The Woodlands, Texas 77381

(Address of principal executive offices and Zip Code)

(281) 863-3000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001			LXRX			The Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02     Results of Operation and Financial Condition

On November 6, 2025, we issued a press release to report our financial results for the quarter ended September 30, 2025. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits

(d)    Exhibits

Exhibit No.						Description
99.1			—			Press Release of Lexicon Pharmaceuticals, Inc. dated November 6, 2025
EX-104			—			Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Lexicon Pharmaceuticals, Inc.
Date: November 6, 2025			By:			/s/ Brian T. Crum
						Brian T. Crum
						Senior Vice President and General Counsel

FAQ

What did Lexicon Pharmaceuticals (LXRX) report in this Form 8-K?

Lexicon Pharmaceuticals furnished a Form 8-K to state that it issued a press release reporting its financial results for the quarter ended September 30, 2025, which is attached as Exhibit 99.1.

Which period do the Lexicon Pharmaceuticals (LXRX) results in this 8-K cover?

The financial results discussed in the attached press release cover Lexicon Pharmaceuticals’ quarter ended September 30, 2025.

Where can investors find the detailed Lexicon Pharmaceuticals (LXRX) quarterly results?

Detailed quarterly financial results are contained in Lexicon Pharmaceuticals’ press release attached to the Form 8-K as Exhibit 99.1.

Is the Lexicon Pharmaceuticals (LXRX) financial information in this 8-K considered filed with the SEC?

No. Lexicon Pharmaceuticals specifies that the information in this report and Exhibit 99.1 is being furnished, not filed, for purposes of Section 18 of the Exchange Act.

What exhibits are included with this Lexicon Pharmaceuticals (LXRX) 8-K?

The 8-K includes Exhibit 99.1, a press release dated November 6, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Lexicon Pharmaceuticals (LXRX) Form 8-K?

The Form 8-K was signed on behalf of Lexicon Pharmaceuticals, Inc. by Brian T. Crum, Senior Vice President and General Counsel.